 DUBLIN, Ireland, Feb. 10, 2021 GLOBE NEWSWIRE -- Avadel Pharmaceuticals plc Nasdaq: AVDL, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference, which is being held February 24th to 26th. 